-52.6%
RBLX vs MRNA
+945.0%
-997.7%
-66.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +8.5% | +13.1% | -4.6% | +7.9% |
| 7D | -7.5% | +20.6% | -28.1% | -8.3% |
| 30D | +10.6% | +27.1% | -16.5% | +9.2% |
| 3M | +33.3% | +353.4% | -320.1% | +16.8% |
| 6M | +3.7% | +446.3% | -442.6% | -12.7% |
| YTD | -39.1% | +776.2% | -815.3% | -52.7% |
| 1Y | -52.6% | +987.9% | -1,040.6% | -65.6% |
| All | -52.6% | +945.0% | -997.7% | -65.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling